JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ito, C.
Right arrow Articles by Watanabe, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ito, C.
Right arrow Articles by Watanabe, T.

Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine

C Ito, K Onodera, E Sakurai, M Sato and T Watanabe

Department of Psychiatry, Tohoku University School of Medicine, Japan.

In this study, we examined the changes in neuronal histamine (HA) release in the rat striatum after acute and repeated administration of methamphetamine (METH). We studied the regulation of METH-induced HA release by dopamine receptors and the relationship between METH-induced HA release and stereotyped behavior. Acute administration of METH (1 mg/kg) significantly increased HA release 60 min later. Pretreatments with the dopamine D2 antagonists sulpiride and haloperidol blocked the METH-induced increase of HA release, whereas pretreatment with a dopamine D1 antagonist, SCH23390, did not. Moreover, repeated administration of METH (3 mg/kg) greatly enhanced the METH-induced increase of HA release 60, 80, 100, 120 and 180 min after rechallenge of METH (1 mg/kg). Repeated treatment with haloperidol and METH blocked the increase of HA release induced by the rechallenge of METH. The METH- induced increase of HA release was still found after the METH-induced stereotyped behavior decreased in both acute and repeated administrations of METH. These findings suggest that the METH-induced HA release in the striatum is controlled by dopamine D2 receptors and may play an important inhibitory role in the METH-induced stereotyped behavior. Furthermore, a persistent change in the HA neuron system through DA neurotransmission may be partially responsible for the METH- induced behavioral sensitization.

Volume 279, Issue 1, pp. 271-276, 10/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Neurosci.Home page
C. Pillot, J. Ortiz, A. Heron, S. Ridray, J.-C. Schwartz, and J.-M. Arrang
Ciproxifan, a Histamine H3-Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat
J. Neurosci., August 15, 2002; 22(16): 7272 - 7280.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Morisset, C. Pilon, J. Tardivel-Lacombe, D. Weinstein, W. Rostene, C. Betancur, P. Sokoloff, J.-C. Schwartz, and J.-M. Arrang
Acute and Chronic Effects of Methamphetamine on Tele-Methylhistamine Levels in Mouse Brain: Selective Involvement of the D2 and not D3 Receptor
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 621 - 628.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Morisset, U. G. Sahm, E. Traiffort, J. Tardivel-Lacombe, J. M. Arrang, and J.-C. Schwartz
Atypical Neuroleptics Enhance Histamine Turnover in Brain Via 5-Hydroxytryptamine2A Receptor Blockade
J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 590 - 596.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1996 by the American Society for Pharmacology and Experimental Therapeutics.